Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Applying science in practice: the optimization of biological therapy in rheumatoid arthritis.

Ramiro S, Machado P, Singh JA, Landewé RB, da Silva JA.

Arthritis Res Ther. 2010;12(6):220. doi: 10.1186/ar3149. Epub 2010 Nov 4. Review.

2.

Indirect and mixed treatment comparisons in arthritis research.

Ades AE, Madan J, Welton NJ.

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv5-9. doi: 10.1093/rheumatology/ker241. Review.

PMID:
21859707
3.

Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.

Singh JA, Cameron DR.

J Manag Care Pharm. 2012 May;18(4 Supp C):S1-18. Review.

PMID:
22656072
4.

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.

Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH.

Ann Rheum Dis. 2014 Mar;73(3):516-28. doi: 10.1136/annrheumdis-2013-204577. Epub 2014 Jan 7. Review. Erratum in: Ann Rheum Dis. 2015 Jan;74(1):320.

PMID:
24399231
5.

Applying biologic therapies to the management of patients with rheumatoid arthritis.

Epstein AA, Kremer JM, Siegel E.

Semin Arthritis Rheum. 2014 Feb;43(4):577. doi: 10.1016/j.semarthrit.2013.12.004. Epub 2013 Dec 14.

PMID:
24485351
6.

Assessment and management of rheumatoid arthritis.

Haraoui B.

J Rheumatol Suppl. 2009 Jun;82:2-10. doi: 10.3899/jrheum.090124. Review. Erratum in: J Rheumatol. 2009 Aug;36(8):1851.

PMID:
19509324
7.

Biologics in rheumatoid arthritis: where are we going?

Fechtenbaum M, Nam JL, Emery P.

Br J Hosp Med (Lond). 2014 Aug;75(8):448-9, 451-6. doi: 10.12968/hmed.2014.75.8.448. Review.

PMID:
25111096
8.

Rheumatoid arthritis: Evidence-based rather than habit-based treatment options.

Yazici Y.

Nat Rev Rheumatol. 2012 May 29;8(7):374-6. doi: 10.1038/nrrheum.2012.79. No abstract available.

PMID:
22641135
9.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D.

Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25.

10.

Use of biologic agents in rheumatoid arthritis: introduction.

Silman AJ.

Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv3-4. doi: 10.1093/rheumatology/ker239. No abstract available.

PMID:
21859703
11.

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG.

Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641. Review. No abstract available.

12.

Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis.

Combe B.

Joint Bone Spine. 2006 Dec;73(6):587-90. Epub 2006 Sep 14. No abstract available.

PMID:
17071123
13.

Adherence to biologic DMARD therapies in rheumatoid arthritis.

Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L.

Expert Opin Biol Ther. 2010 Sep;10(9):1367-78. doi: 10.1517/14712598.2010.510508. Review.

PMID:
20681888
14.

Biologics in rheumatoid arthritis--recommendations for Swiss practice.

Dudler J, Möller B, Michel BA, Villiger PM.

Swiss Med Wkly. 2011 May 10;141:w13189. doi: 10.4414/smw.2011.13189.

15.

[Rheumatoid arthritis: milestones in classification and treatment].

Fiehn C.

Dtsch Med Wochenschr. 2011 Feb;136(5):203-5. doi: 10.1055/s-0031-1272510. Epub 2011 Jan 26. Review. German.

PMID:
21271482
16.
17.

'Treat to target' for rheumatoid arthritis in 2014--time tested triple therapy or logical biologics?

Mok MY, Danda D.

Int J Rheum Dis. 2014 Jan;17(1):1-3. doi: 10.1111/1756-185X.12313. No abstract available.

PMID:
24472259
18.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology..

Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721. No abstract available.

19.

Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.

Cohen SB, Cohen MD, Cush JJ, Fleischmann RM, Mease PJ, Schiff MH, Simon LS, Weaver AL.

J Rheumatol Suppl. 2008 Feb;81:4-30; quiz 31-4. Review.

PMID:
19193621
20.

Supplemental Content

Support Center